Reply letter to "Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial"

被引：1
|
作者：
Hadigal, Sanjay [1 ]
Colombo, Laura [2 ]
Haughie, Scott [3 ]
机构：
[1] Viatris, Dept Med Affairs, Bengaluru 560087, Karnataka, India
[2] Viatris, Dept Med Affairs, Milan, Italy
[3] Viatris, Dept Biometr, Sandwich, Kent, England
来源：
HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2022年 / 18卷 / 05期
关键词：
Number needed to vaccinate; standard-dose quadrivalent vaccine; high-dose quadrivalent vaccine; vaccine shortage; at-risk group prioritization; vaccine coverage; influenza vaccine; flu;
D O I：
10.1080/21645515.2022.2085470
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
A recent study reported that the high-dose quadrivalent influenza vaccine provided superior immunogenicity and efficacy versus the standard-dose quadrivalent vaccine in the elderly. However, we need to view these results in terms of public health benefits as well. The Number Needed to Vaccinate (NNV) is an important tool to measure the benefit of a given vaccine. Further, NNV evaluates the benefits of a vaccine in preventing and controlling communicable diseases. Considering the target of vaccination and coverage of 75% not met in the elderly in Europe, it is important not to prioritize one vaccine over the other, but rather to increase the vaccine coverage with all the available vaccines.
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial
    Pepin, Stephanie
    Nicolas, Jean-Francois
    Szymanski, Henryk
    Leroux-Roels, Isabel
    Schaum, Thomas
    Bonten, Marc
    Icardi, Giancarlo
    Shrestha, Anju
    Tabar, Cynthia
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (12) : 5475 - 5486
  • [2] Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults? 60 years of age: Results from a phase III, randomized clinical trial
    Sanchez, Leilani
    Nakama, Takahiro
    Nagai, Hideaki
    Matsuoka, Osamu
    Inoue, Satoshi
    Inoue, Takahiro
    Shrestha, Anju
    Pandey, Aseem
    Chang, Lee-Jah
    De Bruijn, Iris
    [J]. VACCINE, 2023, 41 (15) : 2553 - 2561
  • [3] Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate
    Nham, Eliel
    Seong, Hye
    Hyun, Hakjun
    Yoon, Jin Gu
    Noh, Ji Yun
    Cheong, Hee Jin
    Kim, Woo Joo
    Kim, Eugene
    Choi, Leejung
    Lee, Jung-Min
    Song, Joon Young
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (03)
  • [4] High-Dose Inactivated Influenza Vaccine Quadrivalent for Older Adults
    Chahine, Elias B.
    [J]. ANNALS OF PHARMACOTHERAPY, 2021, 55 (01) : 89 - 97
  • [5] Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: A phase III, randomized trial
    Tinoco, Juan Carlos
    Pavia-Ruz, Noris
    Cruz-Valdez, Aurelio
    Doniz, Carlos Aranza
    Chandrasekaran, Vijayalakshmi
    Dewe, Walthere
    Liu, Aixue
    Innis, Bruce L.
    Jain, Varsha K.
    [J]. VACCINE, 2014, 32 (13) : 1480 - 1487
  • [6] An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population
    Fochesato, Anna
    Sottile, Sara
    Pugliese, Andrea
    Marquez-Pelaez, Sergio
    Toro-Diaz, Hector
    Gani, Ray
    Alvarez, Piedad
    Ruiz-Aragon, Jesus
    [J]. VACCINES, 2022, 10 (08)
  • [7] Immunogenicity and safety of a multi-dose quadrivalent inactivated influenza vaccine in individuals aged 6 months to 17 years: a randomized phase III trial
    Ojeda, Joyce
    Luis Arredondo, Jose
    Salcedo, Perla
    Paredes-Paredes, Mercedes
    Dupuy, Martin
    Petit, Celine
    Chabanon, Anne Laure
    Rivas, Enrique
    Gurunathan, Sanjay
    De Bruijn, Iris
    Pepin, Stephanie
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (06) : 1380 - 1384
  • [8] Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years
    Kieninger, Dorothee
    Sheldon, Eric
    Lin, Wen-Yuan
    Yu, Chong-Jen
    Bayas, Jose M.
    Gabor, Julian J.
    Esen, Meral
    Fernandez Roure, Jose Luis
    Narejos Perez, Silvia
    Sanchez, Carmen Alvarez
    Feng, Yang
    Claeys, Carine
    Peeters, Mathieu
    Innis, Bruce L.
    Jain, Varsha
    [J]. BMC INFECTIOUS DISEASES, 2013, 13
  • [9] Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years
    Dorothee Kieninger
    Eric Sheldon
    Wen-Yuan Lin
    Chong-Jen Yu
    Jose M Bayas
    Julian J Gabor
    Meral Esen
    Jose Luis Fernandez Roure
    Silvia Narejos Perez
    Carmen Alvarez Sanchez
    Yang Feng
    Carine Claeys
    Mathieu Peeters
    Bruce L Innis
    Varsha Jain
    [J]. BMC Infectious Diseases, 13
  • [10] Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model
    Kathrin Pahmeier
    Christian Speckemeier
    Silke Neusser
    Jürgen Wasem
    Janine Biermann-Stallwitz
    [J]. PharmacoEconomics, 2023, 41 : 1539 - 1550
12345